Zydus Lifesciences Ltd on Saturday said the US health regulator has issued six observations after inspecting its Gujarat-based API manufacturing unit.
"We wish to inform that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the group's API (active pharmaceutical ingredient) unit located at Dabhasa in Gujarat," the drug firm said in a regulatory filing.
The inspection was conducted from April 21-25, 2025.
"The inspection concluded with 6 observations and none of them were related to data integrity," Zydus Lifesciences said.
ADVERTISEMENT
The company is confident of addressing the observations expeditiously, it added.
ADVERTISEMENT
RECOMMENDED FOR YOU
Maharashtra CM Fadnavis, Adani Group’s Jeet Adani Inspect Navi Mumbai International Airport Project
Jul 12, 2025
ICICI Prudential Life Shares Pare Losses After Q1 New Business Premium Rise
Jul 10, 2025
Alembic Pharma Shares Surge After USFDA Nod For New Ovarian Cancer Drug
Jun 30, 2025
.png?rect=0%2C0%2C3500%2C1969&w=75)
NATCO Pharma's Hyderabad API Manufacturing Facility Gets One Observation From USFDA
Jun 13, 2025
POPULAR
1
HCLTech Q1 Preview: Muted Growth Likely; Analysts Expect Narrower FY26 Guidance Band
2
Market Resilience Challenged By Trump’s Weekend Tariff Salvo
3
India's Russian Oil Buy Hits 11-Month High In June
4
Musk Says Trump Should 'Just Release Epstein Files As Promised'
5